Email Updates

You are here

AVAC in the News

  • The fog around the largest AIDS vaccine study ever conducted began to lift today, as Thai and U.S. researchers for the first time publicly presented a detailed analysis of their data to over 1000 scientists gathered here at an annual meeting.

    October 20, 2009
    Science Insider
  • Researchers from the U.S. Army and Thailand announced last month they had found the first vaccine that provided some protection against HIV. But a second analysis of the $105 million study, not disclosed publicly, suggests the results may have been a fluke, according to AIDS scientists who have seen it.

    October 12, 2009
    Wall Street Journal
  • The vaccine — known as RV 144, a combination of two genetically engineered vaccines, neither of which had worked before in humans — was declared a qualified success after a six-year clinical trial on more than 16,000 volunteers in Thailand. Those who were vaccinated became infected at a rate nearly one-third lower than the others, the sponsors said Thursday morning.

    September 24, 2009
    New York Times
  • Trying to fight misconceptions about the link between H.I.V. transmission and circumcision.

    March 3, 2009
    New York Times
  • A vaginal gel made by Indevus Pharmaceuticals Inc. showed first signs that such a product might protect women from the AIDS virus.

    February 9, 2009
  • Nearly four years after political pressure shut down two trials that would have tested whether a once-a-day pill could prevent high-risk HIV-negative people from catching the AIDS-causing virus, there’s a surge of renewed interest in the concept, known as Pre-Exposure Prophylaxis, or PrEP.

    December 1, 2008
    Scientific American
  • Since a study by Bailey in 2006 found the operation drops the HIV infection rate in men by 60 percent, the procedure most often performed at birth has become a popular elective surgery among grown men in southern Africa.

    July 31, 2008
  • The trial, called PAVE 100, would have tested whether a vaccine could help control HIV infection. The vaccine regimen was developed by the NIAID’s Vaccine Research Center and comprised a DNA vaccine containing HIV genes, with a modified cold virus carrying HIV genes as a booster.

    July 18, 2008
  • The US National Institutes of Health scrubbed plans to test its AIDS vaccine due to concerns about its safety and effectiveness, 10 months after the collapse of a clinical trial for a similar vaccine from Merck & Co.

    July 18, 2008
    Wall Street Journal